<?xml version="1.0" encoding="UTF-8"?>
<TEI xml:space="preserve" xmlns="http://www.tei-c.org/ns/1.0" 
xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" 
xsi:schemaLocation="http://www.tei-c.org/ns/1.0 https://raw.githubusercontent.com/kermitt2/grobid/master/grobid-home/schemas/xsd/Grobid.xsd"
 xmlns:xlink="http://www.w3.org/1999/xlink">
	<teiHeader xml:lang="en">
		<fileDesc>
			<titleStmt>
				<title level="a" type="main">Prognostic impact of B-cell lymphoma 6 in primary CNS lymphoma</title>
			</titleStmt>
			<publicationStmt>
				<publisher/>
				<availability status="unknown"><licence/></availability>
				<date type="published" when="2015-03-26">26 March 2015</date>
			</publicationStmt>
			<sourceDesc>
				<biblStruct>
					<analytic>
						<author>
							<persName><forename type="first">Stephan</forename><surname>Kreher</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Jo</forename><surname>Korinna</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Felicitas</forename><surname>¨hrens</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Peter</forename><surname>Strehlow</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Kathrin</forename><surname>Martus</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Josefine</forename><surname>Borowiec</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Frank</forename><surname>Radke</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Patrick</forename><surname>Heppner</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Eckhard</forename><surname>Roth</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Torsten</forename><surname>Thiel</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Michael</forename><surname>Pietsch</surname></persName>
						</author>
						<author>
							<persName><forename type="first">Agnieszka</forename><surname>Weller</surname></persName>
						</author>
						<author>
							<persName><surname>Korfel</surname></persName>
						</author>
						<author role="corresp">
							<persName><forename type="first">Agnieszka</forename><surname>Korfel</surname></persName>
							<email>agnieszka.korfel@charite.de</email>
						</author>
						<author>
							<affiliation key="aff0">
								<orgName type="department">Department of Hematology and Oncology</orgName>
								<address>
									<addrLine>Campus Benjamin Franklin</addrLine>
									<settlement>Charite Berlin, Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff1">
								<orgName type="department">Institute of Pathology</orgName>
								<address>
									<settlement>Charite Berlin, Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff2">
								<orgName type="department" key="dep1">Institute of Clinical Epidemiology and Applied Biostatistics</orgName>
								<orgName type="department" key="dep2">Institute of Neuropathology</orgName>
								<orgName type="institution">University Tuebingen</orgName>
								<address>
									<settlement>Tuebingen (P.M.)</settlement>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff3">
								<orgName type="department">Brain Tumor Reference Center of the DGNN</orgName>
								<orgName type="institution">University Bonn Medical Center</orgName>
								<address>
									<settlement>Bonn</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff4">
								<orgName type="department">Institute of Neuropathology</orgName>
								<address>
									<settlement>Charite Berlin, Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff5">
								<orgName type="department">Department of Neurology</orgName>
								<orgName type="institution">University Hospital Zurich</orgName>
								<address>
									<settlement>Zurich</settlement>
									<country key="CH">Switzerland</country>
								</address>
							</affiliation>
						</author>
						<author>
							<affiliation key="aff6">
								<orgName type="department">Department of Hematology &amp; Oncology</orgName>
								<address>
									<addrLine>Campus Benjamin Franklin, Hindenburgdamm 30</addrLine>
									<postCode>12200</postCode>
									<settlement>Charite, Berlin</settlement>
									<country key="DE">Germany</country>
								</address>
							</affiliation>
						</author>
						<title level="a" type="main">Prognostic impact of B-cell lymphoma 6 in primary CNS lymphoma</title>
					</analytic>
					<monogr>
						<imprint>
							<date type="published" when="2015-03-26">26 March 2015</date>
						</imprint>
					</monogr>
					<idno type="MD5">C5C252EB1F6170CE44A70D80F03A4D3E</idno>
					<idno type="DOI">10.1093/neuonc/nov046</idno>
					<note type="submission">Received 21 December 2014; accepted 27 February 2015</note>
				</biblStruct>
			</sourceDesc>
		</fileDesc>
		<encodingDesc>
			<appInfo>
				<application version="0.7.2-SNAPSHOT" ident="GROBID" when="2022-05-18T11:13+0000">
					<desc>GROBID - A machine learning software for extracting information from scholarly documents</desc>
					<ref target="https://github.com/kermitt2/grobid"/>
				</application>
			</appInfo>
		</encodingDesc>
		<profileDesc>
			<textClass>
				<keywords>
					<term>BCL-6</term>
					<term>GCB</term>
					<term>non-GCB</term>
					<term>PCNSL</term>
					<term>survival</term>
				</keywords>
			</textClass>
			<abstract>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Background.</s><s>We investigated the prognostic significance of B-cell differentiation status and common B-cell differentiation markers in a post hoc analysis of 119 patients with primary CNS lymphoma (PCNSL) homogeneously receiving high-dose methotrexate (HDMTX) -based chemotherapy within the prospective G-PCNSL-SG1 trial.</s></p><p><s>Methods.</s><s>We evaluated protein expression of B-cell lymphoma 2 (BCL2), BCL6, CD10, and multiple myeloma oncogene 1/interferon regulatory factor 4 (MUM1/IRF4) by immunohistochemistry and analyzed the association with survival.</s></p><p><s>Results.</s><s>The median follow-up of all patients was 67.5 months.</s><s>Median progression-free survival (PFS) was 10.61 months (95% CI: 4.23 -17.00).</s><s>Median overall survival (OS) was 28.85 months (95% CI: 17.96 -39.73).</s><s>Eighty-nine tumors expressed BCL2 (92.7%), 24 (20.5%)</s><s>expressed CD10, 60 (54.1%) expressed BCL6, and 87 (79.0%) expressed MUM1/IRF4.</s><s>On the basis of the Hans algorithm, 80 tumors (73.4%) were classified to the non -germinal center B group, suggesting a post -germinal center origin of PCNSL.</s><s>Expression of BCL6 (cutoff point 30%), but none of the other markers, was associated with shorter PFS (P ¼ .047)</s><s>and OS (P ¼ .035).</s><s>On multivariate analysis, BCL6 expression was associated with shorter PFS (hazard ratio: 1.95, 95% CI: 1.22 -3.12, P ¼ .005)</s><s>but not OS (hazard ratio: 1.85, 95% CI: 0.71 -4.80, P ¼ .21).</s><s>Classification according to Hans algorithm and expression status of the single B-cell markers BCL2, CD10, and MUM1/IRF4 did not correlate with prognosis.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Conclusion.</head><p><s>The findings are limited by the fact that only 23% of all G-PCNSL-SG1 patients could be included in the analysis.</s><s>If validated in an independent cohort, BCL6 may assume clinical relevance as an unfavorable prognostic biomarker in PCNSL.</s></p></div>
			</abstract>
		</profileDesc>
	</teiHeader>
	<text xml:lang="en">
		<body>
<div xmlns="http://www.tei-c.org/ns/1.0"><p><s>Primary CNS lymphoma (PCNSL) is a rare aggressive B-cell neoplasia most frequently of diffuse large B-cell lymphoma (DLBCL) type that is confined to the CNS at time of diagnosis. <ref type="bibr" target="#b0">1</ref></s><s>The formerly poor prognosis of PCNSL has been greatly improved by systemic high-dose methotrexate (HDMTX) -based polychemotherapy, which provides the current standard treatment for all patients with PCNSL.</s><s>Despite substantial improvements in the treatment of PCNSL, the response to HDMTX-based chemotherapy is quite heterogeneous and overall prognosis remains poor, with a median progression-free survival (PFS) of 12 months and a median overall survival (OS) of about 3 years in most studies.</s><s>This necessitates the identification and evaluation of reliable predictive and prognostic biomarkers for risk-stratified treatment decisions. <ref type="bibr" target="#b1">2</ref></s><s>n systemic DLBCL, the prognostic value of different biologic markers has been widely studied.</s><s>Moreover, at least 2 prognostically important subgroups (germinal center B-cell-like and activated B-cell-like DLBCL) were characterized by gene expression profiling using a cDNA microarray. <ref type="bibr" target="#b2">3,</ref><ref type="bibr" target="#b3">4</ref></s><s>Due to the impracticability to perform microarray analysis on every patient, various immunohistochemical (IHC) algorithms have been developed to capture the molecular diversity and stratify patients according to survival. <ref type="bibr">5 -8</ref></s><s>The most widely used method is the Hans algorithm separating DLBCL into germinal center B cell (GCB) and non -germinal center B cell (non-GCB) groups by using antibodies against cluster of differentiation (CD)10, B-cell lymphoma 6 (BCL6), and multiple myeloma oncogene 1/interferon regulatory factor 4 (MUM1/IRF4). <ref type="bibr" target="#b8">9</ref></s><s>In PCNSL, a few small and mostly retrospective studies either failed to observe a prognostic impact of common B-cell differentiation markers or revealed contradictory results. <ref type="bibr">10 -14</ref></s><s>Here we present the analysis of a set of B-cell differentiation markers and their prognostic impact in a cohort from the G-PCNSL-SG1 trial, the largest trial ever conducted in PCNSL.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Materials and Methods</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patients and Treatment</head><p><s>Included in our study were immunocompetent adult patients with newly diagnosed PCNSL in the G-PCNSL-SG1 trial with tumor samples available at one of the 2 reference pathology centers and tumor amount sufficient for IHC analysis.</s><s>The inclusion and exclusion criteria were reported previously. <ref type="bibr" target="#b15">15</ref></s><s>atients were randomly allocated to receive first-line HDMTX-based chemotherapy with or without subsequent whole-brain radiotherapy (WBRT).</s><s>Between May 2000 and August 2006, study therapy consisted of HDMTX (4 g/m 2 as a 4-h i.v.</s><s>infusion with dose reduction according to creatinine clearence) on day 1 of six 14-day cycles; thereafter, patients were to receive HDMTX plus ifosfamide (1.5 g/m 2 ) on days 3 -5 of six 14-day cycles.</s><s>In those assigned to receive first-line chemotherapy followed by radiotherapy, WBRT was to be given at a total dose of 45 Gy in 1.5-Gy fractions.</s><s>Patients allocated to first-line chemotherapy without WBRT who had not achieved complete response to HDMTX-based chemotherapy were given high-dose cytarabine (2 ×3 g/m 2 ) on days 1 -2 of 22-day cycles.</s></p><p><s>The study protocol was approved by local institutional review boards or ethics committees.</s><s>All participants gave written informed consent.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Immunohistochemical Analysis</head><p><s>Immunostaining on paraffin sections was performed centrally at 2 study reference pathology centers for CD10 (clone 56C6, Leica Biosystems), BCL6 (clone LN22, Leica Biosystems; clone PG-B6p, Dako), BCL2 (clone100/D5, Leica Biosystems; clone 124, Dako), and MUM1/IRF4 (clone MUM1p, Dako) using an automated immunostainer (BondMax, Leica Biosystems; Benchmark XT, Roche-Ventana).</s><s>Antigen retrieval was performed using appropriate conditions, bound antibodies were made visible employing a Bond Polymer Refine DAB or ultra-View Universal DAB detection kit (Roche-Ventana), developed and counterstained using the manufacturer ′ s protocols and reagents.</s></p><p><s>Immunohistological labeling of BCL2, CD10, BCL6, and MUM1/IRF4 was visually analyzed and interpreted according to the methods and cutoff points previously published by Horn and colleagues. <ref type="bibr" target="#b16">16</ref></s><s>For BCL6 staining, tumors with more than 30% positively labeled cells were considered positive.</s><s>Tumors were further classified into GCB and non-GCB subgroups according to their expression of CD10, BCL6, and MUM1/IRF4 using the methods and cutoff points (.30%) published by Hans et al. <ref type="bibr" target="#b8">9</ref> Tumors with CD10 expression or BCL6 expression without expression of MUM1/IRF4 were defined as GCB.</s><s>The remaining tumors were classified as non-GCB.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Statistics</head><p><s>Progression-free survival was defined as the time from study entry to first progression or death from any cause.</s><s>Overall survival was defined as the time from study entry to death.</s><s>PFS and OS were estimated by the Kaplan -Meier method.</s><s>Group comparisons were carried out using the log-rank test.</s><s>Additionally, simple and multiple Cox proportional hazards regression models were calculated, and hazard ratios (HRs) including 2-sided 95% CIs were calculated.</s><s>The variables included in the multiple Cox models were determined by forward and backward variable selection leading to identical models.</s><s>Nonsignificant variables were not included in the final models.</s><s>Distribution of patients' characteristics to different groups was analyzed by the chi-square test.</s><s>Mean values of independent groups were compared with Student's t-test.</s><s>The level of significance was .05</s><s>(two-sided).</s><s>Commercially available software was used (SPSS for Windows, release 21.0).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Results</head></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Patient Characteristics and Clinical Outcome</head><p><s>As central collection of tumor tissue was not intended at the time of study enrollment, all available tumor material from participating centers was collected.</s><s>Of 526 eligible patients treated in the G-PCNSL-SG1 trial, sufficient tumor material of 119 patients was available for the present IHC analysis.</s><s>The main patient characteristics, treatment, and outcome are summarized in Table <ref type="table" target="#tab_0">1</ref>.</s><s>With the exception of multifocal brain involvement and type of initial surgery for PCNSL, patient characteristics were comparable to those of study patients not included in this analysis (Supplementary Table <ref type="table" target="#tab_0">S1</ref>).</s><s>However, there was a nonsignificant trend to better PFS (P ¼ .057)</s><s>and OS (P ¼ .056) in patients included in our IHC analyses.</s></p><p><s>The median follow-up of all patients studied here was 67.5 months.</s><s>The median PFS was 10.6 months (95% CI: 4.2 -17.00); the median OS was 28.9 months (95% CI: 18-39.7).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Immunohistochemical Profiles</head><p><s>Eighty-nine of 96 tumors (92.7%) expressed BCL2 and 24 of 117 tumors (20.5%) expressed CD10.</s><s>BCL6 and MUM1/IRF4 were expressed in 60 of 111 (54.1%) and 87 of 110 (79.0%) tumors, respectively.</s><s>Fifty-three tumors of the BCL6-positive tumors coexpressed MUM1/IRF4 (88.3%).</s><s>Twenty-nine tumors (26.6%) were classified as GCB and 80 (73.4%) as non-GCB.</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Prognostic Analysis</head><p><s>Among the biologic markers, only BCL6 expression correlated with shorter PFS and OS (P ¼ .047</s><s>and P ¼ .035,</s><s>respectively; Fig. <ref type="figure" target="#fig_0">1</ref>).</s><s>On univariate analysis, the association of BCL6 was significant for both PFS (HR: 1.53, 95% CI: 1.01 -2.34, P ¼ .047)</s><s>Kreher et al.: Prognostic impact of BCL6 in primary CNS lymphoma and OS (HR: 1.66, 95% CI: 1.04 -2.65, P ¼ .035).</s><s>On multivariate analysis, however, a significant association with PFS only was found (HR: 1.95, 95% CI: 1.22 -3.12, P ¼ .005)</s><s>(Table <ref type="table" target="#tab_1">2</ref>).</s><s>No other biologic markers tested correlated with outcome.</s><s>Particularly, classification according to the Hans algorithm revealed no significant difference between GCB and non-GCB subgroups with respect to survival outcome.</s><s>Patient characteristics and response to treatment did not differ between BCL6-positive and -negative patients except for number of brain lesions (Supplementary Table <ref type="table" target="#tab_1">S2</ref>), with BCL6 expression being significantly associated with multifocal brain involvement (BCL6 positive: 33.3% vs BCL6 negative: 15.7%).</s></p><p><s>When the impact of commonly accepted clinical risk factors in PCNSL was tested, a significant association of age (HR: 1.027, 95% CI: 1.003 -1.05, P ¼ .026)</s><s>and Karnofsky performance score (KPS) (HR: 0.99, 95% CI 0.97 -1.00, P ¼ .044)</s><s>with OS was found on univariate analysis.</s><s>The Memorial Sloan Kettering Cancer Center (MSKCC) score, which is deduced from age and KPS, showed in multivariate analyses a prognostic association with both PFS (HR: 1.87, 95% CI: 1.15 -3.04, P ¼ 0.011) and OS (HR: 2.95, 95% CI: 1.22-7.13,</s><s>P ¼ .016).</s><s>Multifocal brain involvement was significantly associated with shorter PFS (HR: 1.79, 95% CI: 1.14 -2.80, P ¼ .011) on univariate and shorter OS (HR: 2.72, 95% CI: 1.18 -6.28, P ¼ .019) on multivariate analysis.</s><s>To exclude that the effect of multifocal disease was due to confounding with the type of surgery, we performed adjusted and stratified analysis for these 2 factors for OS and PFS.</s><s>In both adjusted analyses, multifocal disease remained significant after inclusion of type of surgery: PFS odds ratio ¼ 1.78, P ¼ .012;</s><s>OS odds ratio ¼ 2.77, P ¼ .012.</s><s>In cases with resection, the odds ratio for PFS was 2.06 (P ¼ .043)</s><s>and for OS 2.13 (P ¼ .23); in cases with biopsy, the odds ratio for PFS was 1.58 (P ¼ .131)</s><s>and for OS 2.97 (P ¼ .044)</s><s>(the lack of significance in some subgroups was most probably due to their small size).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Discussion</head><p><s>Our data confirm previous studies indicating an activated B-cell-like immunophenotype and post-germinal center origin of most PCNSL <ref type="bibr">12,17 -19</ref> with frequent expression of the activation marker MUM1/IRF4, infrequent CD10 expression, and expression of BCL6, a marker of germinal center, in about half of the cases.</s><s>In normal B cells, BCL6 and MUM1/IRF4 are exclusively expressed, <ref type="bibr" target="#b20">20</ref> and a high percentage of BCL6/MUM1/IRF4 coexpression has been shown to be a characteristic feature of PCNSL compared with systemic DLBCL. <ref type="bibr">9,12,21 -23</ref></s><s>Confirming previous analyses, the vast majority of our BCL6-positive tumors  Kreher et al.: Prognostic impact of BCL6 in primary CNS lymphoma coexpressed MUM1/IRF4, which indicates the activated immunophenotype of PCNSL. <ref type="bibr" target="#b12">12,</ref><ref type="bibr" target="#b21">21</ref></s><s>Additionally, most PCNSL of our series belonged to the non-GCB group on the basis of the Hans algorithm, which is in accordance with earlier IHC analyses <ref type="bibr">12,17 -19</ref> and gene expression profiling analysis of 21 PCNSL cases. <ref type="bibr" target="#b24">24</ref></s><s>he prognostic utility of B-cell differentiation status and various B-cell differentiation markers to predict outcome in PCNSL patients is currently questionable.</s><s>The available data concerning this issue are based on mostly retrospective studies with small patient numbers and heterogeneous treatment schedules. <ref type="bibr">10 -14,18,19,21,25,26</ref></s><s>We here investigated expression and prognostic significance of B-cell differentiation markers in the so far largest cohort of PCNSL patients homogeneously receiving HDMTX-based chemotherapy in the prospective G-PCNSL-SG1 trial.</s><s>BCL2 as an anti-apoptotic protein and normally downregulated in GCB has been shown to be an independent poor prognostic indicator for systemic DLBCL. <ref type="bibr" target="#b27">27,</ref><ref type="bibr" target="#b28">28</ref></s><s>In our series, we did not observe a correlation of BCL2 expression with PFS or OS.</s><s>Considering the low frequency of BCL2-negative PCNSL, BCL2 expression seems to be more a characteristic than a prognostic feature in PCNSL.</s><s>The expression status of the single B-cell markers CD10 and MUM1/IRF4 also did not correlate with prognosis, which is in accordance with previous analyses by Braaten et al <ref type="bibr" target="#b26">26</ref> and others. <ref type="bibr" target="#b12">12,</ref><ref type="bibr" target="#b14">14</ref></s><s>However, the percentage of CD10-positive tumors  Previous analyses of the prognostic significance of BCL6 expression in PCNSL yielded controversial results.</s><s>Lossos et al <ref type="bibr" target="#b13">13</ref> reported an independent positive association with PFS (and nearly significant with OS), and Braaten et al <ref type="bibr" target="#b26">26</ref> found an independent and significant positive association with OS.</s><s>Both were retrospective studies with heterogeneously treated patients.</s><s>Moreover, an unusually low positivity threshold of only 10% was used by Braaten et al, resulting in an expression frequency of 79%.</s><s>In contrast, Momota et al <ref type="bibr" target="#b14">14</ref> found an independent negative association of BCL6 expression with PFS.</s><s>In the only prospective multicenter trial addressing this question (CALGB 50202), BCL6 expression significantly correlated with shorter survival. <ref type="bibr" target="#b11">11</ref></s><s>Our findings confirm a negative correlation of BCL6 expression with outcome in PCNSL.</s><s>Reasons for discrepancy with other studies could be the retrospective nature of previous studies, few patient numbers with consequent limited statistical power and possibility of confounding variables, nonuniform treatment, and different immunophenotype and classification methods among different studies.</s><s>Interestingly, there seems to be a correlation between BCL6 expression and negative clinical characteristics in PCNSL.</s><s>Camilleri-Broet et al <ref type="bibr" target="#b12">12</ref> found an association with higher age and worse performance status.</s><s>In the present analysis, a correlation between BCL6 expression and multifocal brain involvement was found.</s><s>Multifocal brain involvement and inferior survival outcome were findings in the whole G-PCNSL-SG1 cohort <ref type="bibr" target="#b29">29</ref> and have been reported by others. <ref type="bibr" target="#b30">30</ref></s><s>n our series, we did not observe a significant prognostic difference between the GCB and non-GCB subgroups.</s><s>This is in line with several smaller studies. <ref type="bibr" target="#b12">12,</ref><ref type="bibr" target="#b14">14,</ref><ref type="bibr" target="#b18">18,</ref><ref type="bibr" target="#b25">25</ref></s><s>ur study has several limitations that have to be regarded.</s><s>Although based on the randomized controlled G-PCNSL-SG1 trial, the presented data are a formerly unplanned post hoc analysis of only 23% of all G-PCNSL-SG1 patients with an-unintended-positive selection bias for analyzed patients.</s><s>The bias was due to selection of patients on the basis of availability of large tumor amount, which resulted in a higher percentage of patients with ,2 tumor lesions and consecutively subtotal or total tumor resection.</s><s>These factors were associated with better outcome in the total G-PCNSL-SG1 study population <ref type="bibr" target="#b29">29</ref> and might explain the nonsignificant but potentially biologically important trend to a superior prognosis in patients included in our IHC analyses.</s><s>It remains unclear how this bias might have impacted our findings.</s><s>Further shortcomings of the study are the number of patients analyzed and the number of events (PFS: 99, OS: 83).</s><s>Although high compared with previous studies, both might have been too low for some outcome differences to become significant, and the multivariate analysis has to be interpreted with caution.</s><s>Even though the selection of variables was identical with forward and backward methods, a change of values in a small number of patients might have led to different models.</s><s>This may also explain the differences between univariate and multivariate analyses for several factors that showed substantially higher odds ratios in multivariate compared with univariate analysis (eg, MSKCC score and multifocal brain involvement in the analysis of OS).</s></p><p><s>Most of our patients (74.7%) were treated with HDMTX alone, which was the standard first-line treatment regimen at the time of study initiation.</s><s>The type of chemotherapy did not have a significant prognostic impact in our uni-and multivariate analyses, but the number of patients might have been too small.</s><s>Thus, we cannot exclude that the survival difference between the BCL6-positive and BCL6-negative groups within our investigation could have been due to the less effective treatment regimen and therefore might not be applicable for patients undergoing an intensified first-line treatment.</s></p><p><s>In conclusion, our findings confirm an activated B-cell-like immunophenotype and post-germinal center origin of PCNSL and indicate BCL6 expression as a valuable biomarker for inferior prognosis.</s><s>In view of the fact that several previous studies reported contradicting results, further prospective studies are necessary to validate our results.</s></p></div><figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_0"><head>Fig. 1 .</head><label>1</label><figDesc><div><p><s>Fig. 1.</s><s>Comparison of PFS and OS according to BCL6 expression.</s></p></div></figDesc><graphic coords="3,138.39,563.07,312.66,151.09" type="bitmap" /></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" xml:id="fig_1"><head></head><label></label><figDesc><div><p><s>-positive vs negative expression.</s><s>k GCB vs non-GCB according to Hans algorithm.</s><s>Kreher et al.: Prognostic impact of BCL6 in primary CNS lymphoma might have been too low, increasing the potential for confounding variables.</s></p></div></figDesc></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_0"><head>Table 1 .</head><label>1</label><figDesc><div><p><s>Patient characteristics, treatment, and treatment response</s></p></div></figDesc><table><row><cell>Characteristics</cell><cell>All Patients, N ¼ 119; n (%)</cell></row><row><cell>Median age, y (range)</cell><cell>63 (26 -83)</cell></row><row><cell>Males</cell><cell>62 (52.1)</cell></row><row><cell>KPS, median</cell><cell>70</cell></row><row><cell>MSKCC score</cell><cell></cell></row><row><cell>1</cell><cell>13 (10.9)</cell></row><row><cell>2</cell><cell>59 (49.6)</cell></row><row><cell>3</cell><cell>31 (26.1)</cell></row><row><cell>No specification</cell><cell>16 (13.4)</cell></row><row><cell>Serum LDH elevated</cell><cell>23 (19.3)</cell></row><row><cell>No specification</cell><cell>59 (49.6)</cell></row><row><cell>Meningeal involvement</cell><cell>6 (5.0)</cell></row><row><cell>No specification</cell><cell>30 (25.2)</cell></row><row><cell>Number of cerebral lesions</cell><cell></cell></row><row><cell>0 -1</cell><cell>82 (68.9)</cell></row><row><cell>≥2</cell><cell>30 (25.2)</cell></row><row><cell>No specification</cell><cell>7 (5.9)</cell></row><row><cell>HDMTX vs HDMTX/IFO</cell><cell>89/30</cell></row><row><cell>WBRT</cell><cell>75 (63.0)</cell></row><row><cell>Response to HDMTX-based chemotherapy</cell><cell></cell></row><row><cell>Complete response</cell><cell>53 (44.5)</cell></row><row><cell>Partial response</cell><cell>20 (16.8)</cell></row><row><cell>Stable disease</cell><cell>6 (5.0)</cell></row><row><cell>Progressive disease</cell><cell>27 (22.7)</cell></row><row><cell>No specification</cell><cell>13 (10.9)</cell></row><row><cell>Median PFS, mo (95% CI)</cell><cell>10.61 (4.23-17.00)</cell></row><row><cell>Median OS, mo (95% CI)</cell><cell>28.85 (17.96-39.73)</cell></row></table><note><p><s>Abbreviations: LDH, lactate dehydrogenase; IFO, ifosfamide.</s></p></note></figure>
<figure xmlns="http://www.tei-c.org/ns/1.0" type="table" xml:id="tab_1"><head>Table 2 .</head><label>2</label><figDesc><div><p><s>Univariate and multivariate analyses for PFS and OS</s></p></div></figDesc><table><row><cell></cell><cell cols="2">Univariate Analysis</cell><cell></cell><cell cols="2">Multivariate Analysis</cell><cell></cell></row><row><cell></cell><cell>HR</cell><cell>P</cell><cell>95% CI</cell><cell>HR</cell><cell>P</cell><cell>95% CI</cell></row><row><cell>PFS</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Age a</cell><cell>1.01</cell><cell>.32</cell><cell>0.99 -1.03</cell><cell>n.d.</cell><cell>-</cell><cell>-</cell></row><row><cell>KPS b</cell><cell>0.99</cell><cell>.23</cell><cell>0.98 -1.01</cell><cell>n.d.</cell><cell>-</cell><cell>-</cell></row><row><cell>Gender c</cell><cell>0.81</cell><cell>.29</cell><cell>0.54 -1.20</cell><cell>0.69</cell><cell>.108</cell><cell>0.44-1.08</cell></row><row><cell>Multifocal brain involvement d</cell><cell>1.79</cell><cell>.011</cell><cell>1.14-2.80</cell><cell>1.20</cell><cell>.49</cell><cell>0.71-2.03</cell></row><row><cell>MSKCC score e</cell><cell>1.40</cell><cell>.14</cell><cell>0.89 -2.20</cell><cell>1.87</cell><cell>.011</cell><cell>1.15-3.04</cell></row><row><cell>LDH f</cell><cell>1.27</cell><cell>.43</cell><cell>0.70 -2.28</cell><cell>1.41</cell><cell>.32</cell><cell>0.72-2.76</cell></row><row><cell>Surgery (biopsy vs resection)</cell><cell>1.28</cell><cell>.24</cell><cell>0.85 -1.91</cell><cell>0.94</cell><cell>.80</cell><cell>0.57-1.54</cell></row><row><cell>HDMTX vs HDMTX/IFO</cell><cell>0.99</cell><cell>.97</cell><cell>0.62 -1.58</cell><cell>1.00</cell><cell>1.00</cell><cell>0.60-1.67</cell></row><row><cell>BCL2 g</cell><cell>1.28</cell><cell>.60</cell><cell>0.52 -3.17</cell><cell>1.09</cell><cell>.86</cell><cell>0.43-2.77</cell></row><row><cell>BCL6 h</cell><cell>1.53</cell><cell>.047</cell><cell>1.01-2.34</cell><cell>1.95</cell><cell>.005</cell><cell>1.22-3.12</cell></row><row><cell>CD10 i</cell><cell>0.81</cell><cell>.42</cell><cell>0.49 -1.34</cell><cell>0.82</cell><cell>.46</cell><cell>0.47-1.40</cell></row><row><cell>MUM1/IRF4 j</cell><cell>0.96</cell><cell>.89</cell><cell>0.58 -1.60</cell><cell>0.77</cell><cell>.37</cell><cell>0.43-1.37</cell></row><row><cell>GCB/non-GCB k</cell><cell>1.12</cell><cell>.65</cell><cell>0.70 -1.80</cell><cell>1.20</cell><cell>.49</cell><cell>0.72-2.00</cell></row><row><cell>OS</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>Age a</cell><cell>1.027</cell><cell>.26</cell><cell>1.003-1.05</cell><cell>n.d.</cell><cell>-</cell><cell>-</cell></row><row><cell>KPS b</cell><cell>0.99</cell><cell>.44</cell><cell>0.97-1.00</cell><cell>n.d.</cell><cell>-</cell><cell>-</cell></row><row><cell>Gender c</cell><cell>0.75</cell><cell>.20</cell><cell>0.49 -1.16</cell><cell>0.48</cell><cell>.091</cell><cell>0.20-1.13</cell></row><row><cell>Multifocal brain involvement d</cell><cell>1.47</cell><cell>.11</cell><cell>0.91 -2.39</cell><cell>2.72</cell><cell>.019</cell><cell>1.18-6.28</cell></row><row><cell>MSKCC score e</cell><cell>1.66</cell><cell>.041</cell><cell>1.02-2.70</cell><cell>2.95</cell><cell>.016</cell><cell>1.22-7.13</cell></row><row><cell>LDH f</cell><cell>1.10</cell><cell>.77</cell><cell>0.59 -2.05</cell><cell>1.89</cell><cell>.38</cell><cell>0.46-7.80</cell></row><row><cell>Surgery (biopsy vs resection)</cell><cell>1.17</cell><cell>.50</cell><cell>0.75 -1.82</cell><cell>0.82</cell><cell>.67</cell><cell>0.33-2.02</cell></row><row><cell>HDMTX versus HDMTX/IFO</cell><cell>0.92</cell><cell>.76</cell><cell>0.53 -1.60</cell><cell>0.37</cell><cell>.19</cell><cell>0.084-1.63</cell></row><row><cell>BCL2 g</cell><cell>0.94</cell><cell>.89</cell><cell>0.38 -2.33</cell><cell>0.68</cell><cell>.62</cell><cell>0.16-3.01</cell></row><row><cell>BCL6 h</cell><cell>1.66</cell><cell>.035</cell><cell>1.04-2.65</cell><cell>1.85</cell><cell>.21</cell><cell>0.71-4.80</cell></row><row><cell>CD10 i</cell><cell>0.61</cell><cell>.09</cell><cell>0.35 -1.07</cell><cell>1.00</cell><cell>1.00</cell><cell>0.39-2.57</cell></row><row><cell>MUM1/IRF4 j</cell><cell>1.00</cell><cell>.99</cell><cell>0.57 -1.77</cell><cell>2.13</cell><cell>.32</cell><cell>0.48-9.41</cell></row><row><cell>GCB/non-GCB k</cell><cell>1.46</cell><cell>.17</cell><cell>0.86 -2.48</cell><cell>1.14</cell><cell>.79</cell><cell>0.44-2.98</cell></row><row><cell>≥2 lesions vs 0 -1 cerebral lesions.</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>e MSKCC score 3 vs 1/2.</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>f Elevated vs normal LDH.</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>g BCL2-positive vs negative expression.</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row><row><cell>h BCL6-positive vs negative expression.</cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell><cell></cell></row></table><note><p><s>Abbreviations: n.d., not determined; LDH, lactate dehydrogenase; IFO, ifosfamide.</s><s>a Age ≥60 y vs ,60 y. b 10% increase in KPS.</s><s>In multivariate analyses, age and KPS were not analyzed separately but combined as the MSKCC score.</s><s>c Female vs male sex.</s><s>d</s></p></note></figure>
			<note xmlns="http://www.tei-c.org/ns/1.0" place="foot">Neuro-Oncology</note>
		</body>
		<back>
			<div type="annex">
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Supplementary Material</head><p><s>Supplementary material is available online at Neuro-Oncology (http://neuro-oncology.oxfordjournals.org/).</s></p></div>
<div xmlns="http://www.tei-c.org/ns/1.0"><head>Funding</head><p><s>The G-PCNSL-SG1 trial was supported by German Cancer Aid.</s><s>This research received no grant from any funding agency.</s></p><p><s>Conflict of interest statement.</s><s>The authors report no potential conflicts of interest.</s></p></div>			</div>
			<div type="references">

				<listBibl>

<biblStruct xml:id="b0">
	<analytic>
		<title level="a" type="main">Diagnosis and treatment of primary CNS lymphoma</title>
		<author>
			<persName><forename type="first">A</forename><surname>Korfel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">U</forename><surname>Schlegel</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nat Rev Neurol</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="317" to="327" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b1">
	<analytic>
		<title level="a" type="main">Treatment for primary CNS lymphoma: the next step</title>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">E</forename><surname>Abrey</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Yahalom</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Deangelis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">18</biblScope>
			<biblScope unit="issue">17</biblScope>
			<biblScope unit="page" from="3144" to="3150" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b2">
	<analytic>
		<title level="a" type="main">Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling</title>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">A</forename><surname>Alizadeh</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">B</forename><surname>Eisen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">E</forename><surname>Davis</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Nature</title>
		<imprint>
			<biblScope unit="volume">403</biblScope>
			<biblScope unit="issue">6769</biblScope>
			<biblScope unit="page" from="503" to="511" />
			<date type="published" when="2000">2000</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b3">
	<analytic>
		<title level="a" type="main">The use of molecular profiling to predict survival after chemotherapy for diffuse large-B-cell lymphoma</title>
		<author>
			<persName><forename type="first">A</forename><surname>Rosenwald</surname></persName>
		</author>
		<author>
			<persName><forename type="first">G</forename><surname>Wright</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">C</forename><surname>Chan</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">N Engl J Med</title>
		<imprint>
			<biblScope unit="volume">346</biblScope>
			<biblScope unit="issue">25</biblScope>
			<biblScope unit="page" from="1937" to="1947" />
			<date type="published" when="2002">2002</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b4">
	<analytic>
		<title level="a" type="main">A new immunostain algorithm classifies diffuse large B-cell lymphoma into molecular subtypes with high accuracy</title>
		<author>
			<persName><forename type="first">W</forename><forename type="middle">W</forename><surname>Choi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">D</forename><surname>Weisenburger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">C</forename><surname>Greiner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">15</biblScope>
			<biblScope unit="issue">17</biblScope>
			<biblScope unit="page" from="5494" to="5502" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b5">
	<analytic>
		<title level="a" type="main">Immunohistochemical profiling based on Bcl-2, CD10 and MUM1 expression improves risk stratification in patients with primary nodal diffuse large B cell lymphoma</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">J</forename><surname>Muris</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">J</forename><surname>Meijer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">W</forename><surname>Vos</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Pathol</title>
		<imprint>
			<biblScope unit="volume">208</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="714" to="723" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b6">
	<analytic>
		<title level="a" type="main">Prognostic impact of activated B-cell focused classification in diffuse large B-cell lymphoma patients treated with R-CHOP</title>
		<author>
			<persName><forename type="first">H</forename><surname>Nyman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Jerkeman</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">L</forename><surname>Karjalainen-Lindsberg</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Mod Pathol</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="issue">8</biblScope>
			<biblScope unit="page" from="1094" to="1101" />
			<date type="published" when="2009">2009</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b7">
	<analytic>
		<title level="a" type="main">Immunohistochemical methods for predicting cell of origin and survival in patients with diffuse large B-cell lymphoma treated with rituximab</title>
		<author>
			<persName><forename type="first">P</forename><forename type="middle">N</forename><surname>Meyer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><surname>Fu</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">C</forename><surname>Greiner</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">29</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="200" to="207" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b8">
	<monogr>
		<title level="m" type="main">Confirmation of the molecular classification of diffuse large B-cell lymphoma by</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">P</forename><surname>Hans</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">D</forename><surname>Weisenburger</surname></persName>
		</author>
		<author>
			<persName><forename type="first">T</forename><forename type="middle">C</forename><surname>Greiner</surname></persName>
		</author>
		<imprint/>
	</monogr>
</biblStruct>

<biblStruct xml:id="b9">
	<analytic>
		<title level="a" type="main">Prognostic impact of BCL6 in primary CNS lymphoma immunohistochemistry using a tissue microarray</title>
		<author>
			<persName><surname>Kreher</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">103</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="275" to="282" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b10">
	<analytic>
		<title level="a" type="main">Clinical importance of Bcl-6-positive non-deep-site involvement in non-HIV-related primary central nervous system diffuse large B-cell lymphoma</title>
		<author>
			<persName><forename type="first">M</forename><forename type="middle">K</forename><surname>Song</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">S</forename><surname>Chung</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><forename type="middle">D</forename><surname>Joo</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurooncol</title>
		<imprint>
			<biblScope unit="volume">104</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="825" to="831" />
			<date type="published" when="2011">2011</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b11">
	<analytic>
		<title level="a" type="main">Intensive chemotherapy and immunotherapy in patients with newly diagnosed primary CNS lymphoma: CALGB 50202 (Alliance 50202)</title>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Rubenstein</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">D</forename><surname>Hsi</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">L</forename><surname>Johnson</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">31</biblScope>
			<biblScope unit="issue">25</biblScope>
			<biblScope unit="page" from="3061" to="3068" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b12">
	<analytic>
		<title level="a" type="main">A uniform activated B-cell-like immunophenotype might explain the poor prognosis of primary central nervous system lymphomas: analysis of 83 cases</title>
		<author>
			<persName><forename type="first">S</forename><surname>Camilleri-Broet</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Criniere</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Broet</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">107</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="190" to="196" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b13">
	<analytic>
		<title level="a" type="main">LMO2 and BCL6 are associated with improved survival in primary central nervous system lymphoma</title>
		<author>
			<persName><forename type="first">C</forename><surname>Lossos</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bayraktar</surname></persName>
		</author>
		<author>
			<persName><forename type="first">E</forename><surname>Weinzierl</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Br J Haematol</title>
		<imprint>
			<biblScope unit="volume">165</biblScope>
			<biblScope unit="issue">5</biblScope>
			<biblScope unit="page" from="640" to="648" />
			<date type="published" when="2014">2014</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b14">
	<analytic>
		<title level="a" type="main">Prognostic value of immunohistochemical profile and response to high-dose methotrexate therapy in primary CNS lymphoma</title>
		<author>
			<persName><forename type="first">H</forename><surname>Momota</surname></persName>
		</author>
		<author>
			<persName><forename type="first">Y</forename><surname>Narita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><forename type="middle">M</forename><surname>Maeshima</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurooncol</title>
		<imprint>
			<biblScope unit="volume">98</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="341" to="348" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b15">
	<analytic>
		<title level="a" type="main">High-dose methotrexate with or without whole brain radiotherapy for primary CNS lymphoma (G-PCNSL-SG-1): a phase 3, randomised, non-inferiority trial</title>
		<author>
			<persName><forename type="first">E</forename><surname>Thiel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Korfel</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Martus</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Lancet Oncol</title>
		<imprint>
			<biblScope unit="volume">11</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="1036" to="1047" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b16">
	<analytic>
		<title level="a" type="main">MYC status in concert with BCL2 and BCL6 expression predicts outcome in diffuse large B-cell lymphoma</title>
		<author>
			<persName><forename type="first">H</forename><surname>Horn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Ziepert</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Becher</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">121</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="2253" to="2263" />
			<date type="published" when="2013">2013</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b17">
	<analytic>
		<title level="a" type="main">Primary central nervous system lymphoma: a clinicopathological study of 75 cases</title>
		<author>
			<persName><forename type="first">M</forename><surname>Preusser</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Woehrer</surname></persName>
		</author>
		<author>
			<persName><forename type="first">O</forename><surname>Koperek</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Pathology</title>
		<imprint>
			<biblScope unit="volume">42</biblScope>
			<biblScope unit="issue">6</biblScope>
			<biblScope unit="page" from="547" to="552" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b18">
	<analytic>
		<title level="a" type="main">Comparison of the expression and prognostic significance of differentiation markers between diffuse large B-cell lymphoma of central nervous system origin and peripheral nodal origin</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">H</forename><surname>Lin</surname></persName>
		</author>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">T</forename><surname>Kuo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">S</forename><surname>Chuang</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">12</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="1152" to="1156" />
			<date type="published" when="2006">2006</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b19">
	<analytic>
		<title level="a" type="main">Bcl-6 predicts improved prognosis in primary central nervous system lymphoma</title>
		<author>
			<persName><forename type="first">O</forename><surname>Levy</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Deangelis</surname></persName>
		</author>
		<author>
			<persName><forename type="first">D</forename><forename type="middle">A</forename><surname>Filippa</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Cancer</title>
		<imprint>
			<biblScope unit="volume">112</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="151" to="156" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b20">
	<analytic>
		<title level="a" type="main">Expression profile of MUM1/ IRF4, BCL-6, and CD138/syndecan-1 defines novel histogenetic subsets of human immunodeficiency virus-related lymphomas</title>
		<author>
			<persName><forename type="first">A</forename><surname>Carbone</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Gloghini</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><forename type="middle">M</forename><surname>Larocca</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">97</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="744" to="751" />
			<date type="published" when="2001">2001</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b21">
	<analytic>
		<title level="a" type="main">Immunohistological profiling by B-cell differentiation status of primary central nervous system lymphoma treated by high-dose methotrexate chemotherapy</title>
		<author>
			<persName><forename type="first">M</forename><surname>Kinoshita</surname></persName>
		</author>
		<author>
			<persName><forename type="first">N</forename><surname>Hashimoto</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Izumoto</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Neurooncol</title>
		<imprint>
			<biblScope unit="volume">99</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="95" to="101" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b22">
	<analytic>
		<title level="a" type="main">Immunohistochemical expression patterns of germinal center and activation B-cell markers correlate with prognosis in diffuse large B-cell lymphoma</title>
		<author>
			<persName><forename type="first">C</forename><forename type="middle">C</forename><surname>Chang</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Mcclintock</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">P</forename><surname>Cleveland</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Am J Surg Pathol</title>
		<imprint>
			<biblScope unit="volume">28</biblScope>
			<biblScope unit="issue">4</biblScope>
			<biblScope unit="page" from="464" to="470" />
			<date type="published" when="2004">2004</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b23">
	<analytic>
		<title level="a" type="main">Clinical impact of the differentiation profile assessed by immunophenotyping in patients with diffuse large B-cell lymphoma</title>
		<author>
			<persName><forename type="first">L</forename><surname>Colomo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Lopez-Guillermo</surname></persName>
		</author>
		<author>
			<persName><forename type="first">M</forename><surname>Perales</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">101</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="78" to="84" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b24">
	<analytic>
		<title level="a" type="main">Gene expression profiling suggests primary central nervous system lymphomas to be derived from a late germinal center B cell</title>
		<author>
			<persName><forename type="first">M</forename><surname>Montesinos-Rongen</surname></persName>
		</author>
		<author>
			<persName><forename type="first">A</forename><surname>Brunn</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Bentink</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Leukemia</title>
		<imprint>
			<biblScope unit="volume">22</biblScope>
			<biblScope unit="issue">2</biblScope>
			<biblScope unit="page" from="400" to="405" />
			<date type="published" when="2008">2008</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b25">
	<analytic>
		<title level="a" type="main">Primary central nervous system lymphoma: immunohistochemical profile and prognostic significance</title>
		<author>
			<persName><forename type="first">D</forename><surname>Raoux</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Duband</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Forest</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuropathology</title>
		<imprint>
			<biblScope unit="volume">30</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="232" to="240" />
			<date type="published" when="2010">2010</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b26">
	<analytic>
		<title level="a" type="main">BCL-6 expression predicts improved survival in patients with primary central nervous system lymphoma</title>
		<author>
			<persName><forename type="first">K</forename><forename type="middle">M</forename><surname>Braaten</surname></persName>
		</author>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">A</forename><surname>Betensky</surname></persName>
		</author>
		<author>
			<persName><forename type="first">L</forename><surname>De Leval</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Clin Cancer Res</title>
		<imprint>
			<biblScope unit="volume">9</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="1063" to="1069" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b27">
	<analytic>
		<title level="a" type="main">Rituximab plus CHOP (R-CHOP) overcomes bcl-2-associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL)</title>
		<author>
			<persName><forename type="first">N</forename><surname>Mounier</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><surname>Briere</surname></persName>
		</author>
		<author>
			<persName><forename type="first">C</forename><surname>Gisselbrecht</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">101</biblScope>
			<biblScope unit="issue">11</biblScope>
			<biblScope unit="page" from="4279" to="4284" />
			<date type="published" when="2003">2003</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b28">
	<analytic>
		<title level="a" type="main">Prognostic significance of Bcl-2 protein expression and Bcl-2 gene rearrangement in diffuse aggressive non-Hodgkin&apos;s lymphoma</title>
		<author>
			<persName><forename type="first">R</forename><forename type="middle">D</forename><surname>Gascoyne</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><forename type="middle">A</forename><surname>Adomat</surname></persName>
		</author>
		<author>
			<persName><forename type="first">S</forename><surname>Krajewski</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Blood</title>
		<imprint>
			<biblScope unit="volume">90</biblScope>
			<biblScope unit="issue">1</biblScope>
			<biblScope unit="page" from="244" to="251" />
			<date type="published" when="1997">1997</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b29">
	<analytic>
		<title level="a" type="main">Surgery for primary CNS lymphoma? Challenging a paradigm</title>
		<author>
			<persName><forename type="first">M</forename><surname>Weller</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Martus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">P</forename><surname>Roth</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">Neuro Oncol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="issue">12</biblScope>
			<biblScope unit="page" from="1481" to="1484" />
			<date type="published" when="2012">2012</date>
		</imprint>
	</monogr>
</biblStruct>

<biblStruct xml:id="b30">
	<analytic>
		<title level="a" type="main">Primary non-Hodgkin&apos;s lymphoma of the CNS treated with BVAM or CHOD/BVAM chemotherapy before radiotherapy</title>
		<author>
			<persName><forename type="first">E</forename><forename type="middle">M</forename><surname>Bessell</surname></persName>
		</author>
		<author>
			<persName><forename type="first">F</forename><surname>Graus</surname></persName>
		</author>
		<author>
			<persName><forename type="first">J</forename><forename type="middle">A</forename><surname>Punt</surname></persName>
		</author>
	</analytic>
	<monogr>
		<title level="j">J Clin Oncol</title>
		<imprint>
			<biblScope unit="volume">14</biblScope>
			<biblScope unit="issue">3</biblScope>
			<biblScope unit="page" from="945" to="954" />
			<date type="published" when="1996">1996</date>
		</imprint>
	</monogr>
</biblStruct>

				</listBibl>
			</div>
		</back>
	</text>
</TEI>
